Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enbrel-Brenzys multiple-switch interchangeability study in rheumatoid arthritis
ACTRN12618000279224Phase 4Completed
- Sponsor
- Emeritus Research
- Start
- Apr 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of etanercept and golimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Emeritus Research. Primary endpoint: Disease activity score at 12 months. Started Apr 2018; status: completed.
02
Drugs
etanerceptgolimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ACTRN12618000279224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000279224.